array:23 [ "pii" => "S0025775314701022" "issn" => "00257753" "doi" => "10.1016/S0025-7753(14)70102-2" "estado" => "S300" "fechaPublicacion" => "2014-09-01" "aid" => "70102" "copyright" => "Elsevier España, S.L.U.. Todos los derechos reservados" "copyrightAnyo" => "2014" "documento" => "article" "crossmark" => 0 "subdocumento" => "fla" "cita" => "Med Clin. 2014;143 Supl 2:8-11" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:2 [ "total" => 505 "formatos" => array:3 [ "EPUB" => 8 "HTML" => 290 "PDF" => 207 ] ] "itemSiguiente" => array:18 [ "pii" => "S0025775314701034" "issn" => "00257753" "doi" => "10.1016/S0025-7753(14)70103-4" "estado" => "S300" "fechaPublicacion" => "2014-09-01" "aid" => "70103" "copyright" => "Elsevier España, S.L.U." "documento" => "article" "crossmark" => 0 "subdocumento" => "fla" "cita" => "Med Clin. 2014;143 Supl 2:12-7" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:2 [ "total" => 1482 "formatos" => array:3 [ "EPUB" => 2 "HTML" => 506 "PDF" => 974 ] ] "es" => array:10 [ "idiomaDefecto" => true "titulo" => "Características y tipos de agonistas del receptor de GLP-1. Una oportunidad más para la individualización terapéutica" "tienePdf" => "es" "tieneTextoCompleto" => 0 "tieneResumen" => array:2 [ 0 => "es" 1 => "en" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "12" "paginaFinal" => "17" ] ] "titulosAlternativos" => array:1 [ "en" => array:1 [ "titulo" => "Characteristics and types of GLP-1 receptor agonists. An opportunity for individualized therapy" ] ] "contieneResumen" => array:2 [ "es" => true "en" => true ] "contienePdf" => array:1 [ "es" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Esteban Jódar" "autores" => array:1 [ 0 => array:2 [ "nombre" => "Esteban" "apellidos" => "Jódar" ] ] ] ] ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0025775314701034?idApp=UINPBA00004N" "url" => "/00257753/00000143000000S2/v1_201410180334/S0025775314701034/v1_201410180334/es/main.assets" ] "itemAnterior" => array:18 [ "pii" => "S0025775314701010" "issn" => "00257753" "doi" => "10.1016/S0025-7753(14)70101-0" "estado" => "S300" "fechaPublicacion" => "2014-09-01" "aid" => "70101" "copyright" => "Elsevier España, S.L.U." "documento" => "article" "crossmark" => 0 "subdocumento" => "fla" "cita" => "Med Clin. 2014;143 Supl 2:2-7" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:2 [ "total" => 767 "formatos" => array:3 [ "EPUB" => 1 "HTML" => 463 "PDF" => 303 ] ] "es" => array:10 [ "idiomaDefecto" => true "titulo" => "Fisiología del GLP-1 y su papel en la fisiopatología de la diabetes mellitus tipo 2" "tienePdf" => "es" "tieneTextoCompleto" => 0 "tieneResumen" => array:2 [ 0 => "es" 1 => "en" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "2" "paginaFinal" => "7" ] ] "titulosAlternativos" => array:1 [ "en" => array:1 [ "titulo" => "The physiology of glucagon-like peptide-1 and its role in the pathophysiology of type 2 diabetes mellitus" ] ] "contieneResumen" => array:2 [ "es" => true "en" => true ] "contienePdf" => array:1 [ "es" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Francisco Javier Escalada" "autores" => array:1 [ 0 => array:2 [ "nombre" => "Francisco Javier" "apellidos" => "Escalada" ] ] ] ] ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0025775314701010?idApp=UINPBA00004N" "url" => "/00257753/00000143000000S2/v1_201410180334/S0025775314701010/v1_201410180334/es/main.assets" ] "es" => array:11 [ "idiomaDefecto" => true "titulo" => "Modulación del efecto incretina en el tratamiento de la diabetes" "tieneTextoCompleto" => 0 "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "8" "paginaFinal" => "11" ] ] "autores" => array:1 [ 0 => array:3 [ "autoresLista" => "Josep Vidal" "autores" => array:1 [ 0 => array:3 [ "nombre" => "Josep" "apellidos" => "Vidal" "email" => array:1 [ 0 => "jovidal@clinic.ub.es" ] ] ] "afiliaciones" => array:1 [ 0 => array:2 [ "entidad" => "Servicio de Endocrinología y Nutrición, Hospital Clínic, Barcelona, España" "identificador" => "aff0005" ] ] ] ] "titulosAlternativos" => array:1 [ "en" => array:1 [ "titulo" => "Modulation of the incretin effect in the treatment of diabetes" ] ] "pdfFichero" => "main.pdf" "tienePdf" => true "PalabrasClave" => array:2 [ "es" => array:1 [ 0 => array:4 [ "clase" => "keyword" "titulo" => "Palabras clave" "identificador" => "xpalclavsec355644" "palabras" => array:9 [ 0 => "Análogo GLP-1" 1 => "Análogo receptor GLP-1" 2 => "Diabetes" 3 => "GIP" 4 => "GLP-1" 5 => "Glucagón" 6 => "Incretina" 7 => "Inhibidor DPP-4" 8 => "Vaciamiento gástrico" ] ] ] "en" => array:1 [ 0 => array:4 [ "clase" => "keyword" "titulo" => "Keywords" "identificador" => "xpalclavsec355643" "palabras" => array:9 [ 0 => "GLP-1 analog" 1 => "GLP-1 analog receptor" 2 => "Diabetes" 3 => "GIP" 4 => "GLP-1" 5 => "Glucagon" 6 => "Incretin" 7 => "DPP-4 inhibitor" 8 => "Gastric emptying" ] ] ] ] "tieneResumen" => true "resumen" => array:2 [ "es" => array:2 [ "titulo" => "Resumen" "resumen" => "<p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">La modulación del efecto incretina ha abierto una nueva estrategia en el tratamiento de la diabetes mellitus tipo 2 (DM2). La potenciación de este mecanismo fisiológico se ha conseguido hasta la fecha por dos vías. De una parte, la inhibición farmacológica de la enzima que degrada fisiológicamente a péptido similar al glucagón-1 (GLP-1), la dipeptidil peptidasa-4 (DPP-4). Por otra, el desarrollo de moléculas agonistas del receptor de GLP-1 (arGLP-1) resistentes a la acción de la DPP-4. Distintos ensayos clínicos han demostrado la mayor eficacia clínica de los arGLP-1, lo cual parecería ligado al alcance de mayores niveles circulantes de GLP-1. En contrapartida, esta parece ser la base también de la mayor tasa de efectos adversos asociados al tratamiento con arGLP-1 en comparación con la inhibición de DPP-4. La valoración de estas y otras características diferenciadoras de ambas familias de fármacos deberá marcar nuestra elección en el tratamiento personalizado de la hiperglucemia en el paciente con DM2.</p>" ] "en" => array:2 [ "titulo" => "Abstract" "resumen" => "<p id="spar0010" class="elsevierStyleSimplePara elsevierViewall">Modulation of the incretin effect has opened up a new strategy in the treatment of diabetes mellitus type 2 (DM2). To date, this physiological mechanism has been boosted in two ways: firstly, by pharmacological inhibition of the enzyme that physiologically degrades glucagon-like peptide-1 (GLP-1) receptor agonists, dipeptidyl peptidase-4 (DPP4); secondly, through the development of GLP-1 agonists (GLP-1a) that are resistant to the action of DPP-4. Several clinical trials have shown the clinical superiority of GLPa, which seems to be linked to higher circulating levels of GLP-1. On the other hand, this higher efficacy also seems to be associated with the higher rate of adverse effects associated with aGLP-1 therapy compared with DPP-4 inhibition. These and other differentiating characteristics of the two drug families will determine the choice of drug therapy in the personalized treatment of hyperglycemia in patients with DM2.</p>" ] ] ] "idiomaDefecto" => "es" "url" => "/00257753/00000143000000S2/v1_201410180334/S0025775314701022/v1_201410180334/es/main.assets" "Apartado" => null "PDF" => "https://static.elsevier.es/multimedia/00257753/00000143000000S2/v1_201410180334/S0025775314701022/v1_201410180334/es/main.pdf?idApp=UINPBA00004N&text.app=https://www.elsevier.es/" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0025775314701022?idApp=UINPBA00004N" ]
Información de la revista
Compartir
Descargar PDF
Más opciones de artículo
Modulación del efecto incretina en el tratamiento de la diabetes
Modulation of the incretin effect in the treatment of diabetes
Josep Vidal
Servicio de Endocrinología y Nutrición, Hospital Clínic, Barcelona, España